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Abstract
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver a scientific opinion on a mixture of xylo-oligosaccharides
(XOS) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is obtained from corncobs
(Zea mays subsp. mays) via enzyme-catalysed hydrolysis and subsequent purification. The main
components of the NF, the oligosaccharides, are resistant to human digestive enzymes and are
fermented by colonic bacteria. The intention is to add the NF to a variety of foods such as bakery and
dairy products, fruit jelly, chocolates and soy-drinks. The information provided on composition,
specifications, production process and stability of the NF, does not raise safety concerns. There were
effects observed in the animal studies with the NF or with other XOS which were considered by the
Panel to be expected from the intake of non-digestible carbohydrates. The Panel notes that the acute
and transient gastrointestinal observed in human intervention studies with the NF or with other XOS
have also been associated with the consumption of other non-digestible carbohydrates. The
Panel concludes that the NF, a mixture of XOS, is safe under the proposed uses and use levels. The
target population is the general population.
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Summary
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver a scientific opinion on a mixture of xylo-oligosaccharides
(XOS) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The assessment, which follows
the methodology set out in the EFSA Guidance on the preparation and presentation of an application
for authorisation of a novel food Regulation (EU) 2015/2283 and in the Commission Implementing
Regulation (EU) 2017/2469, is based on the data supplied in the original application, the initial
assessment by the competent authority of Hungary, the concerns and objections of a scientific nature
raised by the other Member States and the responses of the applicant.
The NF is a mixture of XOS which are obtained from corncobs (Zea mays subsp. mays) via enzyme-
catalysed hydrolysis and subsequent purification. The main components of the NF, the
oligosaccharides, are resistant to human digestive enzymes and are fermented by colonic bacteria. The
intention is to add the NF to a variety of foods such as bakery and dairy products, fruit jelly,
chocolates and soy-drinks.
The information provided on composition, specifications, production process and stability of the NF,
does not raise safety concerns.
The Panel considers that there are no concerns with respect to genotoxicity of the NF.
There were effects observed in the animal studies with the NF or with other XOS which were
considered by the Panel to be expected from the intake of non-digestible carbohydrates.
Human intervention studies, which were carried out with the NF or with other XOS, indicated the
occurrence of acute and transient gastrointestinal effects at the beginning of the consumption of XOS
at doses of 10–12 g/day. The Panel notes that these effects have also been associated with the
consumption of other non-digestible carbohydrates. Therefore, under the proposed condition of use
the Panel considers that the available human data do not raise safety concerns in relation to the NF.
The 95th percentile anticipated daily intake of the NF among the EU surveys ranges between 0.6
and 2.6 g/day for infants, 1.2 and 4.2 g/day for toddlers, 1.5 and 5.9 g/day for children, 1.7 and 7.4
for adolescents and 4.0 and 7.7 for adults. The Panel notes that the anticipated daily intake of the NF
is based on the assumption that a person would consume all proposed food products containing the
maximum added amount of the NF.
In order to assess the anticipated daily intake of the NF, the Panel considers the current dietary
reference value (DRV) and intake data (in the case of infants) of dietary fibre, as a proxy for non-
digestible carbohydrates. The DRVs are 10 g/day for toddlers, 14–16 g/day for children, 19–21 g/day
for adolescents and 25 g/day for adults. The Panel notes that the highest 95th percentile anticipated
daily intake of the NF is below the DRV for dietary fibre in these population groups. Regarding infants,
no DRV for dietary fibre has been determined for this population group. The Panel notes that the
highest 95th percentile anticipated daily intake of the NF for infants is similar or below the average
intake of dietary fibre for this population group.
The Panel considers that the consumption of the NF in the intended foods and at the intended use
levels, in addition to the background dietary exposure of fibre, does not raise safety concerns.
The Panel concludes that the NF, a mixture of XOS, is safe under the proposed uses and use levels.
The target population is the general population.
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 4 May 2016, the company Longlive Europe Food Division Ltd. submitted a request under Article
4 of the Novel Food Regulation (EC) No 258/971 to place on the market xylo-oligosaccharides (XOS) as
a novel food (NF).
On 18 July 2016, the competent authority of Hungary forwarded to the Commission its initial
assessment report, which came to the conclusion that XOS meets the criteria for acceptance of a NF
defined in Article 3(1) of Regulation (EC) No 258/97.
On 20 July 2016, the Commission forwarded the initial assessment report to the other Member
States (MS). Several MS raised objections or submitted comments.
The concerns of a scientific nature raised by the MS can be summarised as follows:
• Complete specifications for the three forms of the NF are needed.
• More information is needed on the stability of the NF, in particular when added to the intended
food categories.
• Questions were raised on the anticipated daily intake of the NF presented by the applicant as it
should take into account all proposed food categories in which the NF is intended to be added,
considering each population group in the target population and mean and high intake.
• Clarifications were sought on toxicological studies: whether they were performed according to
GLP standards and were in line with OECD guidances; whether the test materials corresponded
to the NF.
On 6 September 2017 and in accordance with Article 29(1)(a) of Regulation (EU) No 178/20022,
the Commission asked EFSA to provide a scientific opinion by carrying out the additional assessment
for XOS as a NF in the context of Regulation (EU) No 258/97.
According to Article 35 (1) of Regulation (EU) 2015/22833, any request for placing a NF on the
market within the Union submitted to a Member State in accordance with Article 4 of Regulation (EU)
No 258/97, and for which the final decision has not been taken before 1 January 2018, shall be
treated as an application under Regulation (EU) 2015/2283. This is the case for this application.
In accordance with Article 10 (3) of Regulation (EU) 2015/2283, EFSA shall give its opinion as to
whether the update of the Union List referred to in Article 10 (1) is liable to have an effect on human
health.
2. Data and methodologies
2.1. Data
The safety assessment of this NF is based on data supplied in the original application, the initial
assessment by the competent authority of Hungary, the concerns and objections of a scientific nature
raised by the other MS along with the responses from the applicant and information submitted by the
applicant following EFSA requests for supplementary information.
Administrative and scientific requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in the Commission Implementing Regulation (EU) 2017/24694.
1 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel food ingredients. OJ L 43, 14.2.1997, p. 1–6.
2 Regulation (EU) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
3 Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods, amending Regulation (EU) No 1169/
2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and
of the Council and Commission Regulation (EC) No 1852/2001 (2013/0435 (COD). OJ L 327, 11.12.2015, p. 1–22.
4 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientific
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
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A common and structured format on the presentation of NF applications is described in the EFSA
guidance on the preparation and presentation of a NF application.5 As indicated in this guidance, it is
the duty of the applicant to provide all of the available (proprietary, confidential and published)
scientific data, including both data in favour and not in favour to support the safety of the proposed
NF.
The application did not include a request for the protection of proprietary data (Article 26 of
Regulation (EU) 2015/2283).
2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications and the
principles described in the relevant existing guidance documents from the EFSA Scientific Committee.
The legal provisions for the assessment are laid down in Article 11 of Regulation (EU) 2015/2283 and
in Article 7 of the Commission Implementing Regulation (EU) 2017/2469.
This assessment concerns only risks that might be associated with consumption of the NF under
the proposed conditions of use (i.e. added to a variety of foods) and is not an assessment of the
efficacy of the NF with regard to any claimed benefit.
3. Assessment
3.1. Introduction
The NF is a mixture of XOS which are obtained from corncobs (Zea mays subsp. mays) via enzyme-
catalysed hydrolysis and subsequent purification. The intention is to add the NF in a variety of foods
such as bakery and dairy products, fruit jelly, chocolates and soy-drinks.
3.2. Identity of the NF
The NF is a mixture of XOS, which are oligosaccharides constituted of chains of D-xylose molecules
linked via b(1–4) bonds with a degree of polymerisation (DP) ranging from 2 to 7. The NF is obtained
from corncobs (Z. mays subsp. mays) via hydrolysis using a xylanase followed by a purification
process.
The NF is available in syrup (XOS 70L) or powder (XOS 70P and XOS 95P) form, and is
predominantly composed of the disaccharide xylobiose, the trisaccharide xylotriose and the
tetrasaccharide xylotetraose. Small amounts of higher oligosaccharides (i.e. xylopentaose, xylohexaose
and xyloheptaose) are also present. The XOS content in the NF is at least 70% in the XOS 70L and
XOS 70P forms, and 95% in the XOS 95P form.
3.3. Production process
The NF is obtained from corncobs of Z. mays subsp. mays (genus Zea; family Poaceae), which do
not include kernels, via hydrolysis by a xylanase (EC 3.2.1.8) followed by a purification process.
Corncob powder is soaked in water; after addition of acetic acid, the mixture is subjected to
heating under high temperature and pressure conditions to break down the hemicelluloses. After
cooling to the temperature optimum of the enzyme, xylanase is added to hydrolyse the shortened
xylan chains into oligosaccharides. After separation from the remaining solid material, the
oligosaccharide-containing liquid is purified by treatment with activated carbon powder and by means
of two consecutive cation and anion exchange chromatographic steps. For the liquid XOS product, the
purified solution is concentrated by evaporation. For XOS products in powder form, the liquid is
subjected to filtration using a nano-filter membrane and subsequently concentrated and dried via spray
drying. For XOS 70P, maltodextrin is added to adjust the intended concentration of XOS in the final
product.
According to the applicant, the corncobs used as raw material for the production of the NF are
grown and produced in Northwest Plain of Shandong (China). The corn plants are not genetically
5 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), Turck D, Bresson J-L, Burlingame B, Dean T,
Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle H, Naska A, Neuh€auser-Berthold M, Nowicka G,
Pentieva K, Sanz Y, Siani A, Sj€odin A, Stern M, Tome D, Vinceti M, Willatts P, Engel K-H, Marchelli R, P€oting A, Poulsen M,
Salminen S, Schlatter J, Arcella D, Gelbmann W, de Sesmaisons-Lecarre A, Verhagen H and van Loveren H, 2016. Guidance on
the preparation and presentation of an application for authorisation of a novel food in the context of Regulation (EU)
2015/2283. EFSA Journal 2016;14(11):4594, 24 pp. https://doi.org/10.2903/j.efsa.2016.4594
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modified; negative results from respective PCR tests on corncobs and on a batch of XOS 70L were
provided. Corncobs were also tested for the presence of aflatoxins, heavy metals and residual levels of
pesticides, which were reported to be below the limits of quantification.
According to a certificate provided, the enzyme manufacturer obtained Trichoderma reesei CICC
13052 from the China Center of Industrial Culture Collection (CICC) for the production of the xylanase.
T. reesei has a long history of use in the production of cellulolytic enzymes. The safety of T. reesei
has been reviewed by Nevalainen et al. (1994) and Blumenthal (2004). T. reesei is considered to be
non-pathogenic. However, the Panel noted that Trichoderma reesei was not eligible for Qualified
presumption of safety (QPS) status considering its capacity to produce peptaibols, antimicrobial
peptides, and additional compounds with unknown biological activity (EFSA BIOHAZ Panel, 2013).
Upon request by EFSA, the applicant provided additional information on the specification of the
xylanase. The enzyme complied with the JECFA requirements for food enzymes (JEFCA, 2006) with
regard to lead and microbiological criteria (i.e. Salmonella species, total coliforms). However, for
Escherichia coli, the limit is ‘Not more than 3 MPN (Most Probable Number)/g’, whereas JEFCA requires
that Escherichia coli should be ‘absent in 25 g sample’. The enzyme did not show antibacterial activity.
The fact that the enzyme does not show antibacterial activity indicates that peptaibols are not present
in the food enzyme in amounts that would raise safety concern.
The applicant also provided results on several mycotoxins in the xylanase (i.e. ochratoxin A,
aflatoxins, fumonisins, deoxynivalenol, zearalenone, T-2 toxin and HT-2 toxin) which were below the
limits of detection.
Upon an EFSA request for information on the absence of the enzyme in the NF, the applicant
referred to the low protein concentration (< 0.2 g/100 g), as indicated in the specifications of the NF in
Table 3. In addition, xylanase activity in the NF was reported to be below the limit of detection (10 U/
g) of the applied assay. These results are to be expected taking into account the employed purification
steps of the NF, i.e. active carbon treatment, ion exchange chromatography, concentration and drying.
The Panel considers that the production process is sufficiently described and does not raise safety
concerns.
3.4. Compositional data
The applicant provided compositional data on 56 batches of XOS 70L, 73 batches of XOS 70P and
127 batches of XOS 95P produced between 2012 and 2015 (Table 1).
In addition, data on heavy metal contents and microbiological data were provided for three batches
of XOS 70L, XOS 70P and XOS 95P, respectively (Table 2).
The analyses have been performed at a laboratory accredited according to ISO/IEO 17025:2005
General Requirements for the Competence of Testing and Calibration Laboratories (CNAS-CL01
Accreditation Criteria for the Competence of Testing and Calibration Laboratories) in China.
The Panel considers that the information provided on the composition and the batch-to-batch
variability of the NF is sufficient and does not raise safety concerns.
Safety of xylo-oligosaccharides
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Table 1: Compositional data of batches of XOS-95P, XOS-70P and XOS-70L produced between 2012 and 2015
XOS 95P
(56 batches)
XOS 70P
(73 batches)
XOS 70L
(127 batches)Parameter
Mean Min. Max. Mean Min. Max. Mean Min. Max.
Moisture (%) 2.63 2.58 2.73 2.59 2.23 2.67 72.3 70.3 73.1
Protein (g/100 g) 0.10 0.071 0.2 0.17 0.12 0.18 0.17 0.14 0.18
Ash (%) 0.05 0.03 0.06 0.06 0.04 0.09 0.12 0.10 0.15
pH 3.89 3.5 4.1 4.13 3.96 4.15 4.22 4.00 4.31
Total carbohydrate content (g/100 g) 98.0 97.67 98.33 96.90 94.27 97.90 75.7 74.75 75.91
XOS content (dry basis) (g/100 g) 95.07 95.01 95.39 73.62 71.5 88.2 76.54 71.5 88.2
Other carbohydrates (g/100 g)(a) 2.87 2.50 2.94 7.24 1.5 8.2 23.13 17.31 25.54
Monosaccharides total (g/100 g) 2.23 1.35 2.72 4.49 3.23 5.72 21.1 15.61 23.14
Glucose (g/100 g) 0.95 0.82 1.45 2.38 0.76 3.72 3.19 2.01 3.75
Arabinose (g/100 g) 0.69 0.13 0.89 0.25 0.17 0.58 6.45 4.6 6.59
Xylose (g/100 g) 0.59 0.40 0.98 0.86 0.60 0.98 11.46 9.0 12.8
Disaccharides total (g/100 g) 33.42 33.13 35.86 28.71 24.2 30.9 31.71 30.5 34.0
Xylobiose XOS DP2 (g/100 g) 30.65 30.63 32.96 25.96 21.7 28.0 29.68 28.8 31.6
Cellobiose (g/100 g) 2.77 2.5 2.9 2.75 2.5 2.9 2.03 1.7 2.4
Oligosaccharides total (g/100 g) 65.08 41 77 44.65 41.61 51.1 46.87 43.41 53.16
Xylotriose (XOS DP3) (g/100 g) 31.6 26.7 34.0 21.1 18.1 20.9 21.98 19.9 22.8
Xylotetraose (XOS DP4) (g/100 g) 12.7 7.5 36.9 11.8 10.6 12.3 12.28 12.2 13.2
Xylopentaose (XOS DP5) (g/100 g) 17.5 8.0 19.71 6.31 4.98 7.19 6.46 6.13 7.14
Xylohexaose (XOS DP6) (g/100 g) 4.7 4.0 5.03 3.81 3.26 3.96 2.65 2.38 4.22
XOS DP ≥ 7 (g/100 g) 6.4 5.8 6.6 4.70 4.67 7.75 3.50 2.8 5.8
Maltodextrin (g/100 g)(b) 0 0 0 21 20 25 0 0 0
XOS: xylo-oligosaccharides; DP: degree of polymerisation.
(a): Other carbohydrates include monosaccharides (glucose, xylose and arabinose) and cellobiose.
(b): Maltodextrin content is calculated according to the amount added in the process.
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Table 2: Heavy metal contents and microbiological data for batches of XOS 95P, XOS 70P and XOS 70L
Parameter
XOS 95P XOS 70P XOS 70L
MethodBatch
28.12.2012
Batch
25.4.2013
Batch
1.9.2013
Batch
7.6.2012
Batch
10.9.2013
Batch
28.11.2013
Batch
8.11.2011
Batch
15.3.2013
Batch
18.11.2013
Copper
(mg/kg)
< 5.0 < 5.0 < 5.0 < 5.0 < 5.0 < 5.0 < 5.0 < 5.0 < 5.0 GB/T 5009.13-2003
Lead (mg/kg) < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 < 0.5 GB/T 5009.12-2010
Arsenic
(mg/kg)
< 0.3 < 0.3 < 0.3 < 0.3 < 0.3 < 0.3 < 0.3 < 0.3 < 0.3 GB/T 5009.11-2003
Total colony
forming unit
(cfu/g)
10 10 < 10 10 < 10 < 10 < 10 < 10 5 FDA-BAM Chap3
Salmonella
(cfu/25 g)
Negative Negative Negative Negative Negative Negative Negative Negative Negative FDA-BAM Chap4 and 5
E. coli
(MPN/100 g)
Negative Negative Negative Negative Negative Negative Negative Negative Negative FDA-BAM Chap4
Yeast (cfu/g) < 10 5 < 10 < 10 < 10 < 10 < 10 < 10 < 10 FDA-BAM Chap18
Mould (cfu/g) < 10 5 5 5 < 10 < 10 5 < 10 15 FDA-BAM Chap18
XOS: xylo-oligosaccharides; MPN: most probable number.
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3.4.1. Stability of the NF
The applicant proposed a shelf life of 12 months for XOS 70L and of 24 months for XOS 95P and
XOS 70P.
Heat and pH stability of the NF in aqueous solutions were investigated in model experiments
(Courtin et al., 2008).
To test the heat stability, XOS 95P was dissolved at a concentration of 15% (w/v) in buffers (pH
2.0, 3.0, 7.0 and 11.0), and each solution was kept at 100°C or in a heating block for 5, 10, 15, 20, 30
and 60 min, respectively. The NF did not show substantial decomposition (appr. 1–4% w/w) at low or
neutral pH. In total, 21% and 9% of all glycosidic linkages were cleaved at pH 2.0 and 3.0,
respectively; arabinose linkages were more susceptible to the acid-catalysed hydrolysis than xylose
linkages.
Under alkaline conditions (pH 11.0), 73% of the NF was decomposed after 60 min of incubation at
100°C. The so-called ‘alkaline peeling’ type reaction leads to a cleavage of glycosidic bonds at the
reducing end of the carbohydrate backbone; the reaction results in organic acids and a successive
shortening of the saccharide chain by one carbohydrate unit.
At 121°C, faster decomposition and cleavage of glycosidic linkages via hydrolysis were reported by
the authors (results not shown).
For shelf life stability measurements, XOS 95P solutions in the four buffers were stored at 4°C and
at 37°C, and samples were analysed after 8 and 18 weeks (4°C) and after 1, 3, 7, 14, 30 and 60 days
(37°C). There was no substantial decomposition of XOS 95P at low or neutral pH. At pH 11.0,
decomposition between 67% and 16% (w/w) after 56 days of storage at 37°C and 18 weeks at 4°C,
respectively, were observed.
These model experiments indicate that the NF is heat stable at low and neutral pH; in contrast, at
high pH (11.0) substantial decomposition occurs even at low temperature.
The Panel considers that the data provided sufficient information with respect to the stability of
the NF.
3.4.2. Stability under the intended conditions of use
Liquid milk with 0.5–4.0 g/100 g XOS content was stored for 4 weeks and 83% of the initial XOS
content was measured at the end of the storage period. The XOS content (2 g/100 g XOS) in yoghurt
and powdered milk was reported to be maintained (more than 95%) after 16 days and 5 months,
respectively (GRAS, 2013).
Upon EFSA’s request of information on stability, the applicant provided data on the stability of the
NF in different exemplary foods prepared in a pilot plant. There were no significant changes of the
total contents of XOS 95P, XOS 70P and XOS 70L in the following foods under the indicated storage
conditions:
• Yoghurt (pH 4.6) with XOS 95P (0.34 g/100 g), XOS 70P (0.36 g/100 g), XOS 70L (0.37 g/100 g),
respectively; stored for 2 weeks at 4°C;
• Fruit jelly (pH 3.0) with XOS 95P (2.76 g/100 g), XOS 70P (2.73 g/100 g), XOS 70L (2.69 g/100 g),
respectively; stored for 4 weeks at 20°C;
• Soy drink with XOS 95P (0.33 g/100 g), XOS 70P (0.35 g/100 g), XOS 70L (0.35 g/100 g),
respectively; stored for 3 weeks at 4°C;
• Biscuits with XOS 95P (1.85 g/100 g), XOS 70P (1.85 g/100 g), XOS 70L (1.85 g/100 g),
respectively; stored for 2 weeks at room temperature.
For some of the food examples selected by the applicant, e.g. fruit jelly and biscuits, the durations
chosen for the storage experiments do not reflect the real conditions to be expected. However, taking
into account the nature of the NF and the results of the stability experiments described in
Section 3.4.1, the Panel considers that the data provided sufficient information with respect to the
stability of the NF under the intended conditions of use.
3.5. Specifications of the NF
Upon request from EFSA, the applicant provided specifications for the NF in syrup (XOS 70L) and
powder (XOS 70P and XOS 95P) forms, including information on the analytical method used for each
parameter (Table 3).
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The applicant indicated that analytical tests on the NF have been carried out in Shandong Centre
for Disease Control and Prevention, which is accredited to ISO/IEO 17025:2005 General Requirements
for the Competence of Testing and Calibration Laboratories (CNAS-CL01 Accreditation Criteria for the
Competence of Testing and Calibration Laboratories) for the competence of testing.
The Panel considers that the information provided on the specifications of the NF is sufficient and
does not raise safety concerns.
3.6. History of use of the NF and/or of its source
3.6.1. History of use of the source
The Panel notes that the source of the NF, corncob from Z. mays subsp. mays, is used as feed, but
it has no history of food use.
3.6.2. History of use of the NF
The applicant indicated that XOS have been used as food ingredients (e.g. in dairy products,
beverages, bread, cereal products, and confectionary) and as food supplement in Asia (China, Korea,
Taiwan, Japan). In Japan, XOS are on the market since 1993. XOS 95P and XOS 70P were subject to a
GRAS Notification in 2013 in the USA (GRAS, 2013).
3.7. Proposed uses and use levels and anticipated intake
3.7.1. Target population
The target population as proposed by the applicant is the general population above 1 year of age.
Table 3: Specifications of XOS 95P, XOS 70P and XOS 70L as proposed by the applicant
Parameter XOS-95P XOS-70P XOS-70L Method
Moisture (%) ≤ 5.0 ≤ 5.0 70–75 GB 5009.3-2016
Protein (g/100 g) < 0.2 GB 5009.5-2010
Ash (%) ≤ 0.3 GB 5009.4-2016
pH 3.5–5.0 GB/T 20884-2007
Total carbohydrate content (g/100 g) ≥ 97 ≥ 95 ≥ 70 GB/Z 21922-2008
XOS content (dry basis) (g/100 g) ≥ 95 ≥ 70 ≥ 70 HPLC
Other carbohydrates (g/100 g)(a) 2.5–7.5 2–16 1.5–31.5
Monosaccharides total (g/100 g) 0–4.5 0–13 0–29
Glucose (g/100 g) 0–2 0–5 0–4
Arabinose (g/100 g) 0–1.5 0–3 0–10
Xylose (g/100 g) 0–1.0 0–5 0–15
Disaccharides total (g/100 g) 27.5–48 25–43 26.5–42.5
Xylobiose (XOS DP2) (g/100 g) 25–45 23–40 25–40
Cellobiose (g/100 g) 2.5–3 2–3 1.5–2.5
Oligosaccharides total (g/100 g) 41–77 36–72 32–71
Xylotriose (XOS DP3) (g/100 g) 27–35 18–30 18–30
Xylotetraose (XOS DP4)(g/100 g) 10–20 10–20 8–20
Xylopentaose (XOS DP5) (g/100 g) 3–10 5–10 3–10
Xylohexaose (XOS DP6) (g/100 g) 1–5 1–5 1–5
XOS DP ≥ 7 (g/100 g) 0–7 2–7 2–6
Maltodextrin (g/100 g)(b) 0 20–25 0 –
DP: degree of polymerisation; XOS: xylo-oligosaccharides; HPLC: high-performance liquid chromatography.
(a): Other carbohydrates include monosaccharides (glucose, xylose and arabinose) and cellobiose.
(b): Maltodextrin content is calculated according to the amount added in the process.
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3.7.2. Proposed uses and use levels
The applicant intends to add the NF to a variety of foods: bakery and dairy products, fruit jelly,
chocolates and soy-drinks. Table 4 presents the uses and maximum use levels of the NF as proposed
by the applicant.
3.7.3. Anticipated intake of the NF
The applicant provided estimates of the anticipated daily intake of the NF for each food category
indicated in Table 4, for adults only, based on the summary statistics from the EFSA Comprehensive
European Food Consumption Database.
An additional intake assessment of the NF was performed by EFSA based on the individual
European Union (EU) data from the EFSA Comprehensive Food Consumption Database (EFSA, 2011).
For the estimation of the intake of the NF, EFSA considered the food categories and the maximum use
levels proposed by the applicant in Table 4.
The ranges of the estimated daily intake of the NF (i.e. lowest and highest means and 95th
percentiles among surveys in EU) from foods added with the NF are presented in Table 5 (on a g per
day basis).
3.7.4. Precautions and restrictions of use
The applicant indicated that consumers will be informed about the exact amount of the NF added
to foods and that high consumption might result in gastrointestinal effects.
3.8. Absorption, distribution, metabolism and excretion (ADME)
In vitro and animal studies on degradation of xylobiose or XOS were provided. In addition, animal
and human studies were provided on effects of mixtures of XOS on bacterial counts, short-chain fatty
acids (SCFA) formation and pH in faeces.
The monomer D-xylose is absorbed up to 95% in the small intestine in different species (Huntley
and Patience, 2018) after supplementation in the diet. The absorption decreases with increasing doses
of D-xylose indicating saturation of uptake. In a study with volunteers, 70% of the dose was absorbed
Table 4: Uses and maximum use levels of the NF as proposed by the applicant
Food category(a) Proposed use
Maximum use
level of the NF
Breads and rolls White bread 1.4%
Whole meal bread 1.4%
Breakfast cereals Breakfast cereals 1.4%
Fine bakery wares Biscuit 1.4%
Milk and milk product imitates Soy-drink 0.35%
Fermented milk products Yoghurt 0.35%
Jams, marmalades and fruit spreads Fruit jelly 3%
Chocolate Chocolate 3%
(a): Food categories used for the estimation of the anticipated daily intake of the NF.
Table 5: Anticipated daily intake of the NF on a g per day basis: lowest and highest means and
95th percentiles anticipated daily intake of the NF among the EU surveys based on the
EFSA Comprehensive European Food Consumption Database
Population group
Range of means
g per day
Range of 95th
percentiles g per day
Infants (≤ 11 months) 0.1–0.9 0.6–2.6
Toddlers (12–35 months) 0.4–2.6 1.2–4.2
Children (3–9 years) 0.6–3.6 1.5–5.9
Adolescents (10–17 years) 0.6–3.9 1.7–7.4
Adults (18–64 years) 1.9–3.7 4.2–7.4
Elderly and very elderly (≥ 65 years) 2.2–3.8 4.0–7.7
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after oral administration of 25 g D-xylose (Craig and Ehrenpreis, 1999). A part of D-xylose also reaches
the colon, where it is metabolised by gut bacteria (Huntley and Patience, 2018).
After intravenous infusion of 20 g 14C-xylose to one human, 13.5% of the dose was detected in
expired CO2. About 50% of the dose was excreted unchanged in the urine (Wyngaarden et al., 1957).
Similar values were obtained in another study after infusion of 7.5 mg 14C-xylose (Segal and Foley, 1958).
The metabolism of xylobiose was investigated in vitro and in vivo (Okazaki et al., 1991). No
degradation was found in artificial saliva (containing a-amylase, lysozyme, acid and alkaline
phosphatase and lipase), gastric juice (0.1 N HCl and pepsin), pancreas extract and intestine
brushborder homogenate (both from pigs). Ten Sprague–Dawley rats received xylobiose (100 or 300
mg/kg body weight (bw)) via stomach tube. No xylobiose was detected in urine or faeces 24 h after
application.
Incubation of different species of faecal bacteria with xylose, xylobiose, xylotriose or a mixture of
XOS (obtained from birch wood xylan hydrolysed by Trichoderma-derived xylanase; 22% xylose, 58%
xylobiose, 13% xylotriose and 7% other saccharides) showed that bifidobacteria could degrade the
mixture to a greater extent than other intestinal bacteria (demonstrated by a decrease in pH in the
culture medium) (Okazaki et al., 1990).
In a study a diet containing 6% XOS (Xylooligo 95®, obtained from birch wood hydrolysed by
Trichoderma-derived xylanase, containing mainly xylobiose, xylotriose, xylotetraose, 6% corresponds to
2.4 g/kg bw per day) and 5% cellulose, was fed for 14 days to 10 male Sprague–Dawley rats
(Campbell et al., 1997). As a control, either normal diet without cellulose or diet supplemented with
5% cellulose was used. Compared to the cellulose control, treatment with XOS plus cellulose resulted
in an increased number of overall anaerobic bacteria including bifidobacteria in the faeces, while the
number of aerobic bacteria was decreased. Levels of SCFA in the faeces were increased; in particular,
levels of acetate were statistically significantly higher. Faecal and caecal pH were decreased.
Nine healthy men (50–60 years) ingested daily 5 g XOS (obtained from birch wood xylan
hydrolysed by Trichoderma-derived xylanase; containing mainly xylobiose (58%), xylose (22%) and
xylotriose (13%)) for 3 weeks (Okazaki, 1990). The overall count of intestinal bacteria remained the
same over the duration of the experiment. Faecal pH decreased from 6.16 to 6.29 before
administration to 5.95–6.08 during administration. In five subjects, who showed markedly lowered pH,
SCFA were higher at the end of 3 weeks as compared to the beginning of the study.
In the double-blind study by Finegold et al. (2014), 32 healthy subjects (n = 21 women with age
range of 21–49 years and mean body mass index (BMI) of 24.1 kg/m2; n = 11 men with age range of
23–34 years and mean BMI of 25.6 kg/m2) were randomised to consume daily capsules containing
either 175 mg XOS, 350 mg XOS (produced by the applicant) or maltodextrin (placebo) for 8 weeks.
Bifidobacterium counts increased in both XOS groups compared to the placebo group. Total anaerobic
counts and Bacteroides fragilis group counts were significantly higher in the 350 mg XOS group as
compared to placebo. There were no significant differences in the counts of Lactobacillus,
Enterobacteriaceae and Clostridium between the three groups. XOS intervention had no significant
effect on stool pH, SCFA or lactic acid. The Panel noted that this study was performed with low doses
of the NF.
Fourteen healthy young women were administered with 1.4 or 2.8 g XOS (no specification on the
components) per day for 28 days in the study by Na and Kim (2001). The authors reported a
reduction of faecal pH and an increase in the faecal lactic acid amount in the 2.8 g/day group at day
28 as compared to baseline.
The information provided indicates that D-xylose is readily absorbed and partially metabolised, while
a major part is excreted unchanged in the urine. In contrast, XOS reach the colon unchanged, where
they are degraded by bacteria to SCFA.
3.9. Nutritional information
The Panel notes that the main components of the NF are oligosaccharides, which are resistant to
human digestive enzymes and are fermented by colonic bacteria. Based on the nature of the NF, the
Panel considers that consumption of the NF under the conditions of use is not nutritionally
disadvantageous.
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3.10. Toxicological information
The applicant provided several toxicological studies (genotoxicity, subacute, acute, subchronic and
chronic studies) which have been described in the sections below.
In reply to MS’s comments, the applicant indicated that the toxicological studies were carried out in
Shandong Centre for Disease Control and Prevention, which is accredited by CNAS (China National
Accreditation Service for Conformity Assessment). The applicant indicated that all toxicity tests were
performed in accordance with China State Food and Drug Administration Good Laboratory Practices
standards. The applicant provided the National Chinese Standards according to which the toxicological
studies were performed (GB 15193.3/4/5/7/8-94; GB15193.13-2003; GB15193.13-94).
3.10.1. Genotoxicity
The applicant provided an Assay Inspection Report (summary of unpublished study reports, 2001a;
Fu et al., 2012) on XOS, which were produced by the applicant according to the procedure described
in Section 3.3.
A bacterial reverse mutation test (Ames test) with Salmonella Typhimurium TA97, TA98, TA100, TA102
with or without S-9-mix with five concentrations of XOS (250, 500, 1,000, 2,500 or 5,000 lg/plate) was
negative in two repetitions in the presence and absence of S-9-mix (from rat liver, induced with
polychlorinated biphenyls). The positive control provided positive results. The Panel noted that the study
was not in line with the current standard (i.e. OECD, 1997; TG 471) since one S. Typhimurium strain
(TA1535) in the test was missing.
In a bone marrow micronucleus test, five male and five female [Grade II] Kunming mice were
given XOS doses of 2.5, 5.0 and 10.0 g/kg bw via gavage twice with an interval of 24 h. Animals were
sacrificed 6 h after the second administration. There were no significant differences in the
micronucleus rate between test and control groups. The group given cyclophosphamide (positive
control) provided a positive result. The ratio of polychromatic to normochromatic cells was not
provided.
In a sperm abnormality test, groups of five male [Grade II] Kunming mice received 0, 2.5, 5 and
10 g/kg bw of XOS in distilled water via gavage on five consecutive days. Animals were sacrificed 35
days after the first application and epididymal sperm were obtained. While the positive control
(cyclophosphamide) led to increased counts of abnormal sperm, no increase compared to controls was
detected in sperm from animals treated with XOS.
In a testis chromosome aberration test, groups of five male [Grade II] Kunming mice received 0,
2.5, 5 and 10 g/kg bw of XOS in distilled water via gavage on five consecutive days. Animals were
sacrificed 13 days after the first application; spermatocytes were obtained and processed for
cytogenetic investigation. No increase in the chromosome aberration rate compared to the control was
detected in cells from mice receiving XOS in contrast to the positive control (cyclophosphamide).
The Panel notes that for all genotoxicity studies the results were negative. The Panel notes that
(i) the Ames test was carried out with only four strains, (ii) no in vitro micronucleus assay was
provided and (iii) for all in vivo tests, based on the ADME data, it is not expected that XOS reach the
target tissue. Nonetheless, taking into account also the nature, the source and the production process
of the NF, the Panel considers that there are no concerns with respect to genotoxicity of the NF.
3.10.2. Acute toxicity studies
Acute toxicity studies in rats, mice, and dogs were performed using XOS, produced by the applicant
(according to the procedure described in Section 3.3), at dose levels up to 32 g/kg bw. Soft stools and
vomiting were observed at single doses of XOS of 6, 9, 14 g/kg bw (but not at the dose of 4 g/kg bw)
in dogs; dogs recovered 48 h after administration (summary of unpublished study report, undated).
Soft stool and diarrhoea were observed in rats 2–5 h after taking oral XOS doses of 5 and 10 g/kg bw;
symptoms disappeared after 1 day (Park et al., 1999). Watery stools were also observed in mice taking
a single oral dose of 32 XOS g/kg bw (Gao et al. (2012).
No mortalities occurred up to dose levels of 32 g/kg bw.
3.10.3. Subacute toxicity studies
Wistar rats (10/sex per group) were fed 0, 1, 2 or 4 g/kg bw of XOS (produced by the applicant
according to the procedure described in Section 3.3) for 30 days (summary of Unpublished study
Safety of xylo-oligosaccharides
www.efsa.europa.eu/efsajournal 14 EFSA Journal 2018;16(7):5361
reports, 2001a). No statistically significant differences between XOS and the control group with regard
to the parameters investigated (body weights, feed intake, haematology and clinical biochemistry,
organ weights, histopathological examination) were reported.
A diet-containing 6% XOS (from a different producer than the applicant; derived from birch wood
hydrolysed by Trichoderma-derived xylanase, containing mainly xylobiose, xylotriose, xylotetrose, 6%
corresponds to 2.4 g/kg bw per day) and 5% cellulose was fed for 14 days to 10 male Sprague
Dawley rats (Campbell et al., 1997). As a control, either normal diet without cellulose or diet
supplemented with 5% cellulose were used. Both full and empty colon and caecum weights were
increased, with the effect being more pronounced in the caecum, in the XOS group as compared to
the cellulose control group. Caecum enlargement is a frequent finding in rats after feeding of non-
digestible substances. Caecum and colon weights were not determined in the repeated dose toxicity
studies described below. For effects on caecum content, see Section 3.8.
3.10.4. Subchronic toxicity studies
In a study (Inspection report, 2009; Gao et al. (2012), five groups (10/sex per group) of Wistar
rats were fed diets containing 0% (control), 0.9%, 2.9%, 8.8% and 10% of XOS for 13 weeks,
corresponding to average intakes of 1.1, 3.6, 9.8 and 11.5 g/kg bw per day for females and 1.4, 4.7,
13.8 and 15 g/kg bw per day for males. The test product was produced by the applicant in accordance
with the procedure described in Section 3.3. The test material was composed of xylobiose (29%),
xylotriose (30%), xylotetraose (16%), xylopentaose (8%) and xylohexaose (4%), complying with the
specifications described in Table 4.
Clinical observations were recorded daily and body weights and food consumption were measured
weekly. Ophthalmic examinations were performed at pre-test and just prior to termination. Blood
samples were obtained at days 46 and 91 for analysis of haematology, coagulation and clinical
chemistry parameters. At the end of the study, urine samples were collected for urinalysis, and all
animals were euthanised for necropsy. Selected organs (i.e. brain, heart, lungs, liver, spleen, adrenals,
kidneys, ovary and testes) were weighed. Histological examinations were carried out on several organs.
Transient statistically significant changes in food consumption and in food conversion efficiency, in
different directions, in males and females, were reported in the XOS groups as compared to the
control groups. Starting in week 3, body weights were slightly decreased only in males (dose
dependent, no information on statistical significance was provided).
Statistically significant changes in few clinical chemistry parameters were noted in some XOS
groups as compared to the control groups. A dose-related decrease in triglycerides was observed in
the 2.9%, 8.8% and 10% female groups and in the 10% male group. This effect is treatment related
but is considered not to be adverse. Other statistically significant changes (i.e. a decrease in neutrophil
counts only in the male 0.9% group; a decrease in lymphocytes counts only in the male 2.9% group)
were considered incidental.
The no-observed adverse effect level (NOAEL) in this study is the highest dose tested, i.e. 10% in
the diet, which corresponded to 11.5 and 15 g/kg bw per day in females and males, respectively.
In the study by Park et al. (2000), four groups of 10 male and female SPF SD rats were given, via
gavage, either 0, 0.3, 1.0 or 3.0 g/kg bw of XOS dissolved in water daily for 13 weeks. Upon EFSA’s
request for clarifications on the test material, the applicant indicated that XOS was obtained from a
different producer. The test material was also produced using an enzyme-catalysed hydrolysis of xylan
from corncob; the test material contained xylobiose, xylotriose and 30% water. Ophthalmic
investigations and urinalysis were conducted at the end of the treatment period. During the 13-week of
intervention and the 4-week of recovery, changes in body weights, food and water consumption were
investigated. At week 13 and at the end of the 4-week recovery period, haematological parameters,
organ weights and histopathological findings were investigated. Statistically significant changes in
several parameters were reported. These changes were not dose related and the Panel considered
these as incidental findings. The NOAEL in this study is the highest dose tested (i.e. 3 g/kg bw).
A total of 32 Beagle dogs (7–9 months of age; bw range: 8.1–10.0 kg in females and 8.0–11.0 kg
in males) were randomly divided into four groups (4/sex per group) which were orally administered
pills of XOS for 26 weeks, at doses of 0 (control), 1.25, 2.5 and 5 g/kg bw, once a day for 6 days and
then stopped for one day (Unpublished study report, undated a,b; Gao et al., 2017). One dog/sex per
group was sacrificed after 13 weeks of exposure, two dogs/sex per group after 26 weeks of exposure,
and one dog/sex per group after a 28-day recovery period.
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The test product was produced by the applicant in accordance with the procedure described in
Section 3.3. XOS was composed of 29% xylobiose, 66% xylose-based total fibre (a combination of
30% xylotriose, 16% xylotetraose, 10% xylopentaose, 4% xylohexaose, and 6% xyloglucan), and 5%
monosaccharides (such as glucose, arabinose and xylose).
Number of deaths were recorded throughout the study; dogs were regularly observed for
appearance of signs (e.g. around the eyes, nose, mouth, urethra, etc.), for behavioural activity, for
breathing difficulties, for appetite. Individual body weight and temperature were recorded at the
beginning of the study, at weekly intervals and just prior to sacrifice.
Serum biochemistry, haematology, ophthalmoscopy, electrocardiogram examinations, urine and
stools examinations were carried out at weeks 0, 13, 26, and at the end of the 4-week recovery
period.
Animals were examined for macroscopic morphology, organ weights were determined and
histopathology was carried out at weeks 13, 26 and at the end of the recovery period.
During the study, no animals died. As compared with the control group, all animals in the 5 g/kg
bw group had vomiting and loose stools at the beginning of the study and at some days throughout
the study. Neither vomiting nor loose stools were reported in dogs in the high-dose recovery group. In
the mid-dose group (2.5 g/kg bw), all dogs had loose stools, especially in the beginning of the study.
Neither vomiting nor loose stools were reported in dogs in the mid-dose recovery group. Throughout
the study and after the recovery period, neither vomiting nor loose stools were reported in any of the
animals in the low-dose group (1.25 g/kg bw).
During the 26-week period up to the 4-week recovery period, weekly body weights in the XOS
groups were not statistically significantly different than those in the control group. However, weight
change rate was statistically significantly lower in the high-dose group at weeks 28 and 29 (recovery
period) as compared to the control group, while for the mid- and low-dose group weight was higher
(but not statistically significant) as compared to the control group.
No statistically significant differences between the XOS and the control groups were reported in
haematological and clinical biochemistry parameters and in relative organ weights at weeks 13 and 26
and at the end of the 4-week recovery period. Statistically significant changes were reported in some
electrocardiogram parameters in the recovery period in the high-dose group and in the low-dose group
as compared with placebo, which were not judged as adverse.
Histopathological examinations did not show treatment related effects.
The Panel notes that vomiting which was observed in the high-dose group can be attributed to
consumption of very high doses of a non-digestible substance. Dogs have a similar sensitivity to the
induction of vomiting as humans (Holmes et al., 2009).
The Panel considers that the occurrence of loose stools, which were observed in the high-dose and
in the mid-dose groups, were effects which can be expected from the intake of non-digestible
carbohydrates.
3.10.5. Chronic toxicity of D-xylose
The Panel notes that a 2-year carcinogenicity study on D-xylose has been cited in the GRAS dossier
(Kuroiwa et al., 2005). Upon request, the applicant provided the publication by Kuroiwa et al. (2005).
In this 2-year carcinogenicity study, performed according to the Japanese guideline for food
additives (MHLW, 1996), groups of 50 male and 50 female F344 rats received 0% (control), 2.5% and
5% D-xylose in feed, corresponding to 1,000 and 2,200 mg/kg bw per day in male, and 1,200 and
2,500 mg/kg bw per day in female rats. Soft faeces were observed in male and female rats of the 5%
group. In the 5% group, terminal body weight was reduced by 8% in male and by 6% in female rats
(statistically significant). A statistically significant decrease in absolute and a statistically significant
increase in relative weight of the brain was found in male rats, a decrease of absolute kidney weight
was observed in female rats in the 5% group. There were no histopathological changes reported
attributable to the treatment in these organs. Statistically significantly lower absolute and relative
testes weights in the high-dose group were attributed by the authors to the lower occurrence of
interstitial cell tumours in the testes in xylose-treated animals (72%), compared to controls (92%). No
statistically significant increase in the incidence of any type of neoplastic lesion was found for either
sex in the treated groups.
No statistically significant or biologically relevant differences from the controls were noted in the
XOS groups with regard to clinical signs, mortality and haematological findings.
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Based on this study, the Panel considers that there is no concern for carcinogenicity of D-xylose. In
addition, the Panel considers that there is no concern for toxicity of D-xylose at dose levels equal to or
below 2.5%.
3.10.6. Human studies
XOS produced by the applicant in accordance with the procedure described in Section 3.3 was
investigated in four human intervention studies (unpublished study report, 2001b; Xiao et al., 2012;
Finegold et al., 2014; Yang et al. 2015). The effects of XOS on gastrointestinal parameters, at doses
up to 2 g/day for 8 weeks or sequential weekly doses up to 12 g/day for 3 weeks were assessed. The
only relevant findings were noted in the study by Xiao et al. (2012). This study reported that diarrhoea
occurrence on the first day of consumption of 10–12 g/day XOS was 18–20% as compared to 6% in
controls. No diarrhoea episodes occurred on the first day of consumption of 3–5 g/day of XOS. After 1
week consumption of 10–12 g/day of XOS diarrhoea ratios went back to normal. No other adverse
effects were reported by participants.
The applicant also provided several human intervention studies which were carried out with XOS
from other producers, and which were derived from corncobs or other starting materials. In these
studies, doses of XOS up to 4 g/day for 8 weeks or up to 10 g/day for 5 days were investigated. The
Panel notes that in the uncontrolled study by Kobayashi et al. (1991) (reviewed by Fu et al., 2012), an
increased incidence in diarrhoea (18%) was associated with the consumption of 10 g of XOS at day
one. After 5 days of consumption of 10 g of XOS, the incidence of diarrhoea went back to the initial
incidence of 8%.
The Panel notes that the acute and transient gastrointestinal effects, which were reported with the
consumption of 10–12 g/day XOS in some human intervention studies, have also been associated with
the consumption of other non-digestible carbohydrates. Therefore, under the proposed condition of use
the Panel considers that the available human data do not raise safety concerns in relation to the NF.
3.11. Allergenicity
The NF is obtained from corncob (Z. mays subsp. mays).
The production process involves the use of a xylanase (EC 3.2.1.8), which is produced with
T. reesei, for the hydrolysis step.
According to the specifications (Table 4), the amount of protein in the XOS products is below the
limit of detection (0.2 g/100 g) of the employed analytical techniqueThe activity of the xylanase in the
NF was also below the limit of detection (10 U/g) of the applied assay.
The Panel considers that the likelihood of allergic reactions to the NF is low.
4. Discussion
The NF is a mixture of XOS which are obtained from corncobs (Z. mays subsp. mays) via enzyme-
catalysed hydrolysis and subsequent purification. The main components of the NF, the
oligosaccharides, are resistant to human digestive enzymes and are fermented by colonic bacteria. The
intention is to add the NF to a variety of foods such as bakery and dairy products, fruit jelly,
chocolates and soy-drinks.
The information provided on composition, specifications, production process and stability of the NF,
does not raise safety concerns.
The Panel considers that there are no concerns with respect to genotoxicity of the NF.
There were effects observed in the animal studies with the NF or with other XOS which were
considered by the Panel to be expected from the intake of non-digestible carbohydrates.
Human intervention studies, which were carried out with the NF or with other XOS, indicated the
occurrence of acute and transient gastro-intestinal effects at the beginning of the consumption of XOS
at doses of 10–12 g/day. The Panel notes that these effects have also been associated with the
consumption of other non-digestible carbohydrates. Therefore, under the proposed condition of use,
the Panel considers that the available human data do not raise safety concerns in relation to the NF.
The 95th percentile anticipated daily intake of the NF among the EU surveys ranges from 0.6 to 2.6
g/day for infants, 1.2 to 4.2 g/day for toddlers, 1.5 to 5.9 g/day for children, 1.7 to 7.4 for adolescents
and 4.0 to 7.7 for adults. The Panel notes that the anticipated daily intake of the NF is based on the
assumption that a person would consume all proposed food products containing the maximum added
amount of the NF.
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In order to assess the anticipated daily intake of the NF, the Panel considers the current DRV and
intake data (in the case of infants) of dietary fibre, as a proxy for non-digestible carbohydrates. The
DRVs are 10 g/day for toddlers, 14–16 g/day for children, 19–21 g/day for adolescents and 25 g/day
for adults (EFSA NDA Panel, 2010). The Panel notes that the highest 95th percentile anticipated daily
intake of the NF is below the DRV for dietary fibre in these population groups. Regarding infants, no
DRV for dietary fibre has been determined for this population group (EFSA NDA Panel, 2010). The
Panel notes that the highest 95th percentile anticipated daily intake of the NF for infants is similar to
or below the average intake of dietary fibre for this population group (i.e. 0.3 g/day for a 3 months old
infant and 3.9–8.7 g/day for 6–12 months age infants; Hilbig, 2005).
The Panel considers that the consumption of the NF in the intended foods and at the intended use
levels, in addition to the background dietary exposure of fibre, does not raise safety concerns.
5. Conclusions
The Panel concludes that the NF, a mixture of XOS, is safe under the proposed uses and use levels.
The target population is the general population.
Steps taken by EFSA
1) Letter from the European Commission to EFSA with the request for a scientific opinion on the
safety of xylo-oligosaccharide as a NF. Ref. Ares(2017)4346773, dated 6/9/2017.
2) On 14 September 2017, EFSA received the following documentation: technical dossier on
xylo-oligosaccharide (XOS), submitted by Longlive Europe Food Division Ltd; initial
assessment report (‘Opinion on an application under the novel foods regulation for xylo-
oligosaccharide (XOS)’ carried out by the Food Safety Authority of Hungary; Member States’
comments and objections; responses by the applicant to the initial assessment report and to
the Member States’ comments and objections.
3) On 25 October 2017, EFSA requested the applicant to provide missing information.
4) On 29 November 2017, EFSA received the missing information as submitted by the applicant.
5) On 6 December 2017, the application was considered valid and the scientific evaluation
procedure started.
6) On 24 January 2018, EFSA requested the applicant to provide additional information to
accompany the application and the scientific evaluation was suspended.
7) On 12 April 2018, additional information was provided by the applicant and the scientific
evaluation was restarted.
8) During its meeting on 27 June 2018, the NDA Panel, having evaluated the data, adopted a
scientific opinion on the safety of xylo-oligosaccharide (XOS) as a NF pursuant to Regulation
(EC) No 258/97.
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ADME absorption, distribution, metabolism and excretion
BMI body mass index
bw body weight
cfu colony forming units
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CICC China Center of Industrial Culture Collection
CNAS China National Accreditation Service for Conformity Assessment
DP degree of polymerisation
DRV dietary reference value
EC Enzyme Commission
GLP good laboratory practice
MPN most probable number
MS Member States
NDA EFSA Panel on Dietetic Products, Nutrition and Allergies
NF novel food
NOAEL no-observed adverse effect level
OECD Organisation For Economic Co-Operation and Development
QPS Qualified presumption of safety
SCFA short-chain fatty acids
XOS xylo-oligosaccharides
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